These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 23026741)

  • 1. Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases.
    Southwell AL; Skotte NH; Bennett CF; Hayden MR
    Trends Mol Med; 2012 Nov; 18(11):634-43. PubMed ID: 23026741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene-targeted therapies for the central nervous system.
    Miller TM; Smith RA; Kordasiewicz H; Kaspar BK
    Arch Neurol; 2008 Apr; 65(4):447-51. PubMed ID: 18268183
    [No Abstract]   [Full Text] [Related]  

  • 3. Toxicology of antisense therapeutics.
    Jason TL; Koropatnick J; Berg RW
    Toxicol Appl Pharmacol; 2004 Nov; 201(1):66-83. PubMed ID: 15519609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNAi: a novel antisense technology and its therapeutic potential.
    Dallas A; Vlassov AV
    Med Sci Monit; 2006 Apr; 12(4):RA67-74. PubMed ID: 16572063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense oligonucleotides as therapeutics for malignant diseases.
    Ho PT; Parkinson DR
    Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antisense therapies for neurological diseases].
    Pulst SM
    Nervenarzt; 2019 Aug; 90(8):781-786. PubMed ID: 31165208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oligonucleotide-based therapy for neurodegenerative diseases.
    Magen I; Hornstein E
    Brain Res; 2014 Oct; 1584():116-28. PubMed ID: 24727531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neurodegenerative polyglutamine expansion diseases: physiopathology and therapeutic strategies].
    Ravache M; Abou-Sleymane G; Trottier Y
    Pathol Biol (Paris); 2010 Oct; 58(5):357-66. PubMed ID: 20299163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Long Noncoding RNA with Antisense Oligonucleotide Technology as Cancer Therapeutics.
    Zhou T; Kim Y; MacLeod AR
    Methods Mol Biol; 2016; 1402():199-213. PubMed ID: 26721493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA.
    Mahato RI; Cheng K; Guntaka RV
    Expert Opin Drug Deliv; 2005 Jan; 2(1):3-28. PubMed ID: 16296732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA interference (RNAi)-based therapeutics for treatment of rare neurologic diseases.
    Germain ND; Chung WK; Sarmiere PD
    Mol Aspects Med; 2023 Jun; 91():101148. PubMed ID: 36257857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canine models for human genetic neurodegenerative diseases.
    Barsoum SC; Callahan HM; Robinson K; Chang PL
    Prog Neuropsychopharmacol Biol Psychiatry; 2000 Jul; 24(5):811-23. PubMed ID: 11191715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of liver tumor necrosis factor-alpha expression by targeting delivery of antisense oligonucleotides into Kupffer cells protects rats from fulminant hepatitis.
    Dong L; Zuo L; Xia S; Gao S; Zhang C; Chen J; Zhang J
    J Gene Med; 2009 Mar; 11(3):229-39. PubMed ID: 19189285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small interfering RNAs and antisense oligonucleotides for treatment of neurological diseases.
    Forte A; Cipollaro M; Cascino A; Galderisi U
    Curr Drug Targets; 2005 Feb; 6(1):21-9. PubMed ID: 15720210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Making sense of antisense.
    Vidal L; Blagden S; Attard G; de Bono J
    Eur J Cancer; 2005 Dec; 41(18):2812-8. PubMed ID: 16289851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular biology of channelopathies: impact on diagnosis and treatment.
    Avanzini G; Franceschetti S; Avoni P; Liguori R
    Expert Rev Neurother; 2004 May; 4(3):519-39. PubMed ID: 15853547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral delivery of siRNA and antisense oligonucleotides.
    Akhtar S
    J Drug Target; 2009 Aug; 17(7):491-5. PubMed ID: 19530907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospects for gene therapy in inherited neurodegenerative diseases.
    Cardone M
    Curr Opin Neurol; 2007 Apr; 20(2):151-8. PubMed ID: 17351484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assisted delivery of antisense therapeutics in animal models of heritable neurodegenerative and neuromuscular disorders: a systematic review and meta-analysis.
    van der Bent ML; Paulino da Silva Filho O; van Luijk J; Brock R; Wansink DG
    Sci Rep; 2018 Mar; 8(1):4181. PubMed ID: 29520012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense Drugs Make Sense for Neurological Diseases.
    Bennett CF; Kordasiewicz HB; Cleveland DW
    Annu Rev Pharmacol Toxicol; 2021 Jan; 61():831-852. PubMed ID: 33035446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.